Trade

with

MEI Pharma Inc
(NASDAQ: MEIP)
AdChoices
7.69
-0.19
-2.41%
After Hours :
7.68
-0.01
-0.13%

Open

7.90

Previous Close

7.88

Volume (Avg)

35.43k (65.26k)

Day's Range

7.45-7.99

52Wk Range

5.51-13.98

Market Cap.

170.27M

Dividend Rate ( Yield )

-

Beta

1.31

Shares Outstanding

21.61M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Drug Manufacturers – Specific & Generic
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 0

    • Net Income

    • -27.15M

    • Market Cap.

    • 170.27M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.31

    • Forward P/E

    • -5.81

    • Price/Sales

    • -

    • Price/Book Value

    • 3.77

    • Price/Cash flow

    • -8.13

      • EBITDA

      • -27.10M

      • Return on Capital %

      • -62.88

      • Return on Equity %

      • -67.82

      • Return on Assets %

      • -62.88

      • Book Value/Share

      • 2.09

      • Shares Outstanding

      • 21.61M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 16.00

        • Credit Rating

        • -

        • Analysts

        • 4

        • EPS Estimate

        • -1.34

        • Cashflow Estimate

        • -1.17

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 0.00

          • 7.67

          • Net Income

            YTD/YTD (last year)

          • -

          • -26.33

          • Net Income

            Q/Q (last year)

          • -

          • 197.54

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • -5.42

          • Net Income

            5-Year Annual Average

          • -

          • 3.16

          • Dividends

            5-Year Annual Average

          • -

          • -0.13

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • -

            • 64.72

            • Pre-Tax Margin

            • -

            • 13.77

            • Net Profit Margin

            • -

            • 10.84

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 67.80

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 15.58

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 343.47B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.33

              • Current Ratio

              • 10.68

              • 1.52

              • Quick Ratio

              • 10.57

              • 0.87

              • Interest Coverage

              • -

              • 6.77

              • Leverage Ratio

              • 1.10

              • 1.91

              • Book Value/Share

              • 2.09

              • 16.21

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -5.82

                • 63.69

                • P/E Ratio 5-Year High

                • -43.01

                • 237.47

                • P/E Ratio 5-Year Low

                • -1.46

                • 19.71

                • Price/Sales Ratio

                • -

                • 3.64

                • Price/Book Value

                • 3.77

                • 3.39

                • Price/Cash Flow Ratio

                • -8.13

                • 21.79

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -67.82

                    (-115.50)

                  • 7.86

                    (9.58)

                  • Return on Assets %

                    (5-Year Average)

                  • -62.88

                    (-83.00)

                  • 4.14

                    (5.54)

                  • Return on Capital %

                    (5-Year Average)

                  • -67.82

                    (-115.50)

                  • 5.59

                    (7.66)

                  • Income/Employee

                  • -

                  • 27.79k

                  • Inventory Turnover

                  • -

                  • 1.80

                  • Asset Turnover

                  • -

                  • 0.38

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -27.23M
                  Operating Margin
                  -
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -8.13
                  Ownership

                  Institutional Ownership

                  72.45%

                  Top 10 Institutions

                  64.41%

                  Mutual Fund Ownership

                  30.76%

                  Float

                  62.50%

                  5% / Insider Ownership

                  0.11%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • JPM Global Healthcare

                  •  

                    1,200,944

                  • 0.00

                  • 5.56

                  • Franklin Biotechnology Discovery

                  •  

                    917,702

                  • 153.79

                  • 4.25

                  • Fidelity Advisor® Capital Development

                  •  

                    877,019

                  • 0.00

                  • 4.06

                  • Fidelity® Large Cap Stock Fund

                  •  

                    816,734

                  • 0.00

                  • 3.78

                  • Fidelity Advisor® Diversified Stock Fund

                  •  

                    600,000

                  • 0.00

                  • 2.78

                  • Franklin Biotechnology Discovery Fund

                  •  

                    412,365

                  • 0.00

                  • 1.91

                  • Fidelity Advisor® Large Cap Fund

                  •  

                    290,603

                  • 2.76

                  • 1.34

                  • Vanguard Total Stock Mkt Idx

                  •  

                    269,246

                  • 0.00

                  • 1.25

                  • Tekla Life Sciences Investors

                  •  

                    243,920

                  • 0.00

                  • 1.13

                  • Candriam Eqs L Biotechnology

                  •  

                    225,000

                  • 0.00

                  • 1.04

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity Management and Research Company

                  •  

                    2,565,896

                  • -10.72%

                  • 11.88

                  • New Leaf Venture Management II, LLC

                  •  

                    2,045,475

                  • -88.64%

                  • 11.95

                  • Orbimed Advisors, LLC

                  •  

                    1,924,500

                  • 0.00%

                  • 8.91

                  • Visium Asset Management LLC

                  •  

                    1,660,626

                  • 0.00%

                  • 7.69

                  • Franklin Advisers, Inc.

                  •  

                    1,330,067

                  • +53.94%

                  • 6.16

                  • J P Morgan Asset Management (UK) Ltd

                  •  

                    1,200,944

                  • 0.00%

                  • 5.56

                  • Deerfield Management Co

                  •  

                    1,132,376

                  • -2.76%

                  • 5.24

                  • Aisling Capital LLC

                  •  

                    770,000

                  • 0.00%

                  • 3.56

                  • Vanguard Group, Inc.

                  •  

                    477,301

                  • -4.01%

                  • 2.21

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Drug Manufacturers – Specific & Generic

                  Type

                  Distressed

                  Style

                  Small Growth

                  MEI Pharma Inc was incorporated in Delaware in 2000. The company a development-stage oncology company engaged in the clinical development of novel small molecules for the treatment of cancer based on the central design of naturally o...moreccurring compounds called isoflavones. These compounds interact with specific enzyme targets resulting in inhibition of tumor cell metabolism – a function critical for the survival of cancer cells. The company is currently focused on the clinical development of three drug candidates, ME-143, ME-344 and Pracinostat. In May 2011, it completed the acquisition of certain assets and intellectual property, including those related to ME-143 and ME-344, from Novogen, in accordance with the terms of an Asset Purchase Agreement, dated as of December 21, 2010, between the company, ...moreNovogen and Novogen Research Pty Limited. The U.S. Patent and Trademark Office (USPTO) issued a new patent covering a number of its isoflavone-based compounds, including ME-143 and ME-344, and their pharmaceutical compositions until March 2027. Its competitors include pharmaceutical companies and biotechnology companies, as well as universities and public and private research institutions.lessless

                  Key People

                  Daniel P. Gold,PhD

                  CEO/Director/President

                  Mr. Thomas Zech

                  CFO/Chief Accounting Officer/Secretary

                  Dr. Thomas C. Reynolds,M.D.,PhD

                  Director

                  William D. Rueckert

                  Director

                  Dr. Christine A. White,M.D.

                  Director

                  • MEI Pharma Inc

                  • 11975 El Camino Real

                  • San Diego, CA 92130

                  • USA.Map

                  • Phone: +1 858 792-6300

                  • Fax: -

                  • meipharma.com

                  Incorporated

                  2000

                  Employees

                  19

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: